The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
POT1 germline pathogenic variants and evolving understanding of tumor spectrum: Evidence for lung cancer predisposition.
 
Michael Francis Walsh
No Relationships to Disclose
 
Semanti Mukherjee
Stock and Other Ownership Interests - Regeneron
 
Ming Gao
No Relationships to Disclose
 
Elise Fiala
No Relationships to Disclose
 
Audrey Mauguen
Research Funding - Amgen (Inst); ImaginAb (Inst)
Patents, Royalties, Other Intellectual Property - co-inventor of provisional patent Number 63/193,700, filed on 5/27/21; conversion deadline: 5/27/22; named “Soothsayer”, filed by Office of Technology Development, MSKCC
 
Yelena Kemel
No Relationships to Disclose
 
Chaitanya Bandlamudi
No Relationships to Disclose
 
Miika Mehine
No Relationships to Disclose
 
Maria Isabel Carlo
Honoraria - OncLive/MJH Life Sciences; OncLive/MJH Life Sciences
Other Relationship - Prostate Cancer Foundation; Robert Wood Johnson Foundation
 
Yonina R. Murciano-Goroff
Employment - Memorial Sloan-Kettering Cancer Center
Honoraria - Amgen; Virology Education
Research Funding - Andrew Sabin Family Foundation; Conquer Cancer, the ASCO Foundation; Conquer Cancer, the ASCO Foundation; Druckenmiller Center for Lung Cancer Research; Elucida Oncology (Inst); Endeavor BioMedicines (Inst); Hengrui Pharmaceutical (Inst); Jiangsu Hengrui Pharmaceuticals (Inst); Loxo/Lilly (Inst); Luzsana Biotechnology (Inst); National Cancer Institute; National Cancer Institute; Taiho Oncology (Inst); The Society of Memorial Sloan Kettering
Patents, Royalties, Other Intellectual Property - Rutgers University Press; Wolters Kluwer
Travel, Accommodations, Expenses - AstraZeneca
 
Joseph Vijai
No Relationships to Disclose
 
Ozge Birsoy
No Relationships to Disclose
 
Diana Mandelker
No Relationships to Disclose
 
Michael F. Berger
Consulting or Advisory Role - AstraZeneca; Lilly; PetDx
Patents, Royalties, Other Intellectual Property - Provisional patent pending for "Systems and Methods for Detecting Cancer via cfDNA Screening"
 
David Randolph Jones
Consulting or Advisory Role - AstraZeneca; Merck
Speakers' Bureau - DAVA Oncology; Genentech/Roche
 
Charles M. Rudin
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Bridge Medicines; Daiichi Sankyo/UCB Japan; Earli; Epizyme; Genentech/Roche; Harpoon Therapeutics; Ipsen; Jazz Pharmaceuticals; Kowa; Merck; Syros Pharmaceuticals; Syros Pharmaceuticals
Research Funding - Merck (Inst); Roche/Genentech (Inst)
 
Marc Ladanyi
Consulting or Advisory Role - ADC Therapeutics; AstraZeneca; Bayer; Merck; Paige.AI
Research Funding - Elevation Oncology (Inst); Merus NV (Inst); Rain Therapeutics
 
Zsofia Kinga Stadler
Consulting or Advisory Role - Adverum (I); Genentech/Roche (I); Gyroscope (I); Neurogene (I); Optos (I); Outlook Therapeutics (I); Regeneron (I); Regenxbio (I)
 
Kenneth Offit
Patents, Royalties, Other Intellectual Property - Patent pending on therapeutic applications of targeting ERCC3 mutations in cancer. Diagnosis & treatment of ercc3-mutant cancer US20210137850A1
Other Relationship - AnaNeo Therapeutics